title: Soluble Epoxide Hydrolase Pharmacological Inhibition Ameliorates Experimental Acute Pancreatitis in Mice.
abstract: Acute pancreatitis (AP) is an inflammatory disease, and is one of the most common gastrointestinal disorders worldwide. Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and pharmacological inhibition have beneficial effects in inflammatory diseases. Ephx2 whole-body deficiency mitigates experimental AP in mice, but the suitability of sEH pharmacological inhibition for treating AP remains to be determined. We investigated the effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), which was administered before and after induction of pancreatitis. Serum amylase and lipase levels were lower in TPPU-treated mice compared with controls. In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-α, interleukin Il-1β, and Il-6 were reduced in TPPU-treated mice. Moreover, sEH pharmacological inhibition before and after induction of pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-κB inflammatory response, endoplasmic reticulum stress, and cell death. sEH pharmacological inhibition before and after induction of pancreatitis mitigated cerulein- and arginine-induced AP. This work suggests that sEH pharmacological inhibition may be of therapeutic value in acute pancreatitis.
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Bettaieb
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California.
authors.forename: Samah
authors.initials: S
authors.lastname: Chahed
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California.
authors.forename: Santana
authors.initials: S
authors.lastname: Bachaalany
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California.
authors.forename: Stephen
authors.initials: S
authors.lastname: Griffey
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California.
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Hammock
authors.affiliation: Departments of Nutrition (A.B., S.C., S.B., F.G.H.) and Entomology and Nematology (B.D.H.), and Comparative Pathology Laboratory (S.G.), University of California Davis, Davis, California; and Department of Internal Medicine (F.G.H.) and Comprehensive Cancer Center (B.D.H., F.G.H.), University of California Davis, Sacramento, California fghaj@ucdavis.edu.
authors.forename: Fawaz G
authors.initials: FG
authors.lastname: Haj
mesh_terms: D000681:Amylases / Q000097:blood; D000818:Animals; D001120:Arginine / Q000009:adverse effects; D002108:Ceruletide / Q000009:adverse effects; D004195:Disease Models, Animal; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D005786:Gene Expression Regulation / Q000187:drug effects; D053583:Interleukin-1beta / Q000235:genetics; D015850:Interleukin-6 / Q000235:genetics; D008049:Lipase / Q000097:blood; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D051379:Mice; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
chemical_list: C581572:1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea; C587672:IL1B protein, mouse; D053583:Interleukin-1beta; D015850:Interleukin-6; D010671:Phenylurea Compounds; D010880:Piperidines; D014409:Tumor Necrosis Factor-alpha; C577686:interleukin-6, mouse; D002108:Ceruletide; D001120:Arginine; D008049:Lipase; D000681:Amylases; D004851:Epoxide Hydrolases; C518648:Ephx2 protein, mouse